On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after.
Message from the CEO
IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called feeding tolerance in premature infants. IBP-9414 contains
Lactobacillus reuteri as an active ingredient, which is a human bacterial strain found naturally in breast milk.
This message from the CEO is written during the continuing COVID-19 pandemic which now has been ongoing for one year. The pandemic appeared to be under control during the fall, however the outbreak of COVID worsened during November and December in many parts of the world. I have in previous quarterly reports described the impact of the pandemic on IBT. Simply put, our recruitment rate is affected, but the quality of data generated in the study is not. The bulk of the costs for conducting the study are incurred at the time of recruitment. This means that IBT’s liquidity is expected to be sufficient to complete the study even if the study is concluded at a lat